Outlook Therapeutics Makes Waves in Recent Investor Connect Segment
ISELIN, N.J. — Outlook Therapeutics, Inc. (Nasdaq: OTLK), a pioneering biopharmaceutical firm, continues to make headlines as its President and CEO, Russell Trenary, participated in a significant Virtual Investor CEO Connect segment. This event served as an excellent platform for sharing the company's recent achievements in the realm of ocular health, particularly regarding the treatment of wet age-related macular degeneration (wet AMD).
Key Highlights from the Virtual Investor Connect
During the event, Mr. Trenary provided insightful details about the company’s journey to developing the first authorized ophthalmic formulation of bevacizumab, known as LYTENAVA™ (bevacizumab gamma). This groundbreaking treatment has already received regulatory approval in both the European Union and the United Kingdom, showcasing Outlook Therapeutics’ commitment to advancing care for patients dealing with retinal diseases.
Focus on Wet AMD and LYTENAVA™
Wet AMD affects millions of individuals worldwide, leading to severe vision impairment. As a company dedicated to tackling this challenge, Outlook Therapeutics emphasizes the importance of LYTENAVA™, which has been recognized for its potential to transform treatment paradigms. The formulation has been designed specifically as an ophthalmic solution, making it a pioneering option in the targeted treatment of wet AMD.
Regulatory Approvals and Future Steps
The success of Outlook Therapeutics in securing marketing authorization highlights its innovative research and development efforts. The firm is poised to initiate its commercial launch of LYTENAVA™ in Europe and the UK by the first half of the upcoming calendar year, further expanding access to this essential treatment.
Clinical Trials and FDA Submission Prospects
In the United States, Outlook Therapeutics is actively engaged in clinical trials with ONS-5010, its investigational formulation of LYTENAVA™. The current non-inferiority study is designed to showcase the efficacy of this treatment compared to existing therapies. Should these trials yield favorable results, the company aims to resubmit a Biologics License Application (BLA) to the FDA, marking a significant milestone in bringing this innovative therapy to market for American patients.
Long-Term Vision and Commitment to Patients
As Outlook Therapeutics progresses in its efforts, their unwavering commitment to delivering effective treatment options for wet AMD remains paramount. The company believes that LYTENAVA™ is not just a product but a promise to enhance the quality of life for patients who struggle with vision-related challenges.
Investor Inquiries and Engagement
For those interested in learning more about the developments at Outlook Therapeutics, inquiries can be directed to:
Jenene Thomas
Chief Executive Officer
JTC Team, LLC
T: 908.824.0775
OTLK@jtcir.com
Frequently Asked Questions
What is LYTENAVA™?
LYTENAVA™ is the first approved ophthalmic formulation of bevacizumab specifically for treating wet age-related macular degeneration.
What milestones has Outlook Therapeutics achieved recently?
Recent milestones include obtaining regulatory approval for LYTENAVA™ in the EU and UK, and presenting at the Virtual Investor CEO Connect segment.
When is the commercial launch of LYTENAVA™ expected?
The commercial launch of LYTENAVA™ in the EU and UK is expected in the first half of the upcoming calendar year.
What clinical trials is Outlook Therapeutics conducting?
Outlook is conducting a non-inferiority study of ONS-5010 in the U.S. to support its application for FDA approval.
How can I get in touch with Outlook Therapeutics for investor inquiries?
Investor inquiries can be made by contacting Jenene Thomas at JTC Team, LLC via phone or email provided above.
